GLP1R and Bardet-Biedl syndrome: New mouse model of Bardet-Biedl Syndrome, a rare genetic disease, reveals potential therapeutic targets via transcriptomics and demonstrates proof-of-principle efficacy for GLP1 receptor agonist treatment.